Companies covered: Gilead Sciences, Inc. (NASDAQ:GILD), CRISPR Therapeutics AG (NASDAQ:CRSP), Editas Medicine (NASDAQ:EDIT), bluebird bio, Inc. (NASDAQ:BLUE), ProQR Therapeutics N.V. (NASDAQ:PRQR), Intellia Therapeutics (NASDAQ:NTLA), Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), Genfit SA (OTCMKTS:GNFTF), Viking Therapeutics (NASDAQ:VKTX), InflaRx NV (NASDAQ:IFRX), ChemoCentryx, Inc. (NASDAQ:CCXI), Madrigal Pharmaceuticals (NASDAQ:MDGL), Celgene Corporation (NASDAQ:CELG), VBI Vaccines Inc. (NASDAQ:VBIV), Acer Therapeutics (NASDAQ:ACER), SCYNEXIS, Inc. (NASDAQ:SCYX), Johnson & Johnson (NYSE:JNJ), Takeda Pharmaceutical Co. Ltd. (NYSE:TAK), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Proteon Therapeutics, Inc. (NASDAQ:PRTO), Cellectar Biosciences, Inc. (NASDAQ:CLRB), Chiasma (NASDAQ:CHMA), Veru Inc. (NASDAQ:VERU), Arcturus Therapeutics Ltd. (NASDAQ:ARCT), Medicenna Therapeutics Corp. (NASDAQ:MDNA), Catabasis Pharmaceuticals Inc (NASDAQ:CATB), Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Wave Life Sciences Ltd (NASDAQ:WVE), Merck & Company, Inc. (NYSE:MRK), AbbVie Inc. (NYSE:ABBV), Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Solid Biosciences (NASDAQ:SLDB), Pfizer, Inc. (NYSE:PFE), Biogen Inc. (NASDAQ:BIIB), Amgen Inc. (NASDAQ:AMGN), MacroGenics, Inc. (NASDAQ:MGNX), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), AstraZeneca PLC (NASDAQ:AZN), Novartis AG (NYSE:NVS), Strongbridge Biopharma plc (NASDAQ:SBBP), Moderna (NASDAQ:MRNA), Spark Therapeutics, Inc. (NASDAQ:ONCE), Mustang Bio, Inc. (NASDAQ:MBIO), CEL-SCI Corporation (NYSEAMERICAN:CVM), Eli Lilly and Company (NYSE:LLY), vTv Therapeutics Inc (NASDAQ:VTVT), Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), ProMIS Neurosciences (TSE:PMN), BioPorto A/S (CPH:BIOPOR), InMed Pharmaceuticals, Inc. (OTCMKTS:IMLFF), Protagonist Therapeutics, Inc. (NASDAQ:PTGX), Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), True Leaf Medicine International Ltd. (OTCMKTS:TRLFF), Auris Medical Holding AG (NASDAQ:EARS), Cellectis S.A. (NASDAQ:CLLS), Celyad SA (ADR) (NASDAQ:CYAD), Adaptimmune Therapeutics plc (NASDAQ:ADAP), Mirati Therapeutics, Inc. (NASDAQ:MRTX), Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), T2 Biosystems, Inc. (NASDAQ:TTOO), Nightstar Therapeutics PLC (NASDAQ:NITE), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Blueprint Medicines Corp. (NASDAQ:BPMC), Genocea Biosciences, Inc. (NASDAQ:GNCA), Bristol-Myers Squibb Company (NYSE:BMY), Verastem, Inc. (NASDAQ:VSTM), Bayer AG (ADR) (OTCMKTS:BAYRY), Clovis Oncology, Inc. (NASDAQ:CLVS), Deciphera Pharmaceuticals (NASDAQ:DCPH), BerGenBio ASA (FRA:7BG), Forty Seven (NASDAQ:FTSV), Neon Therapeutics (NASDAQ:NTGN), Gritstone Oncology (NASDAQ:GRTS), OSE Immunotherapeutics SA (OTCMKTS:ORPOF), Roche Holdings Ltd. (ADR) (OTCMKTS:RHHBY), Mesoblast Limited (NASDAQ:MESO), Redhill Biopharma Ltd. (NASDAQ:RDHL), Omeros Corporation (NASDAQ:OMER), ADMA Biologics Inc (NASDAQ:ADMA), DBV Technologies S.A. (NASDAQ:DBVT)
